Cargando…
Remission of aHUS neurological damage with eculizumab
Atypical haemolytic uraemic syndrome (aHUS) is a rare disease characterized by haemolytic microangiopathic anaemia, thrombocytopaenia and acute onset of renal failure, in the absence of Escherichia coli infection. Renal damage usually progresses to end-stage renal disease (ESRD), sometimes being acc...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4370300/ https://www.ncbi.nlm.nih.gov/pubmed/25815183 http://dx.doi.org/10.1093/ckj/sfu144 |
_version_ | 1782362851178971136 |
---|---|
author | Ávila, Ana Vizcaíno, Belén Molina, Pablo Gavela, Eva Perez-Ebri, Maria Pallardó, Luís |
author_facet | Ávila, Ana Vizcaíno, Belén Molina, Pablo Gavela, Eva Perez-Ebri, Maria Pallardó, Luís |
author_sort | Ávila, Ana |
collection | PubMed |
description | Atypical haemolytic uraemic syndrome (aHUS) is a rare disease characterized by haemolytic microangiopathic anaemia, thrombocytopaenia and acute onset of renal failure, in the absence of Escherichia coli infection. Renal damage usually progresses to end-stage renal disease (ESRD), sometimes being accompanied by signs of extrarenal thrombotic microangiopathy (TMA). We report a case of full neurological and haematological recovery after eculizumab treatment in a patient with ESRD secondary to chronic aHUS refractory to plasmatherapy while she was under dialysis. It highlights the use of eculizumab for controlling extrarenal manifestations of aHUS in this population. |
format | Online Article Text |
id | pubmed-4370300 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-43703002015-03-26 Remission of aHUS neurological damage with eculizumab Ávila, Ana Vizcaíno, Belén Molina, Pablo Gavela, Eva Perez-Ebri, Maria Pallardó, Luís Clin Kidney J Contents Atypical haemolytic uraemic syndrome (aHUS) is a rare disease characterized by haemolytic microangiopathic anaemia, thrombocytopaenia and acute onset of renal failure, in the absence of Escherichia coli infection. Renal damage usually progresses to end-stage renal disease (ESRD), sometimes being accompanied by signs of extrarenal thrombotic microangiopathy (TMA). We report a case of full neurological and haematological recovery after eculizumab treatment in a patient with ESRD secondary to chronic aHUS refractory to plasmatherapy while she was under dialysis. It highlights the use of eculizumab for controlling extrarenal manifestations of aHUS in this population. Oxford University Press 2015-04 2015-01-22 /pmc/articles/PMC4370300/ /pubmed/25815183 http://dx.doi.org/10.1093/ckj/sfu144 Text en © The Author 2015. Published by Oxford University Press on behalf of ERA-EDTA. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Contents Ávila, Ana Vizcaíno, Belén Molina, Pablo Gavela, Eva Perez-Ebri, Maria Pallardó, Luís Remission of aHUS neurological damage with eculizumab |
title | Remission of aHUS neurological damage with eculizumab |
title_full | Remission of aHUS neurological damage with eculizumab |
title_fullStr | Remission of aHUS neurological damage with eculizumab |
title_full_unstemmed | Remission of aHUS neurological damage with eculizumab |
title_short | Remission of aHUS neurological damage with eculizumab |
title_sort | remission of ahus neurological damage with eculizumab |
topic | Contents |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4370300/ https://www.ncbi.nlm.nih.gov/pubmed/25815183 http://dx.doi.org/10.1093/ckj/sfu144 |
work_keys_str_mv | AT avilaana remissionofahusneurologicaldamagewitheculizumab AT vizcainobelen remissionofahusneurologicaldamagewitheculizumab AT molinapablo remissionofahusneurologicaldamagewitheculizumab AT gavelaeva remissionofahusneurologicaldamagewitheculizumab AT perezebrimaria remissionofahusneurologicaldamagewitheculizumab AT pallardoluis remissionofahusneurologicaldamagewitheculizumab |